Login to Your Account



Millennium Makes $515M Offer For AnorMED, Tops Genzyme

By Aaron Lorenzo


Wednesday, September 27, 2006
Millennium Pharmaceuticals Inc. agreed to a $515 million premium purchase of AnorMED Inc., outbidding Genzyme Corp. for the Canadian biopharmaceutical firm and its Phase III cancer drug, Mozobil. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription